Indian Pharma Market September 2016 Update - Double Digit Growth Continues

Pharma market has now completed 2 quarters (first half) for this financial year. Market had another month of double digit growth of 12.6%. The market also crossed the Rs. 9000 crore benchmark continuously for the previous 3 months.  So far, two year CAGR for the Indian pharma market has been 12.1%, whereas the four year CAGR is 10.2%

Key Industry Insights for September-16:

1.     Previous month had a growth of 12.6% against 9.8% in September-15. Average Growth for the quarter is 12.8% against 11.5% during the last year

2.     Market clocked Rs. 9792 crore in revenue

3.     Pharma market added Rs. 1094 crore over last year, whereas last year during September, market added up Rs. 779 crore only. For the continuous two months, market crossed Rs. 1000 crore benchmark.


4.     Growth drivers for the previous months were - 6.5% due to volume growth, 2.7% due to price increase, and 3.4% on account of new introductions. Quarter had a volume growth of 6.7% & price growth of 2.8%, the lowest in last 6 quarters.


5.     Volume has been biggest contributor to the overall growth. It has been above 5% for the previous 2 months


6.     Previous month growth on account of price rise was lowest for the last 24 months. The last lowest price growth was in Aug -14. Price component in the overall market growth have been continuously going down since April -16


September Growth Drivers

1.     The market covered under FDCs declined by 23.5%, whereas the market out of FDC purview grew at 13.6%. The Non-FDC market has grown in double digits for the last 3 Months


2.     FDC covered market segment had a huge volume de-growth at -29.3%


3.     Indian companies suffered more. For them, FDC covered product portfolio declined by -28.0%, whereas for MNCs it was -13.1% for September-16 Month


Major Highlights for Month of September-16:


1.     Amongst the top 10 Corporates, Lupin grew fastest at 19.6%, Sun at 17.0%, followed by Abbott at 16.5%

2.     25 Corporates had faster growth than the overall market growth. 34 Corporates had double digit growth.

3.     Amongst the top 50 Corporates, Boehringer Ingelheim had the highest growth of 44.7%, followed by Bharat Serums at 32.2% & Janssen at 28.5%

4.     Amongst the 11-20 ranked Corporates, Micro had the highest growth at 23.5%, followed by DRL at 22.2% & USV at 22.1%

5.     Amongst the 21-30 ranked Corporates, Eris & Unichem had the highest growth at 21.5%, followed by Indoco at 18.1% & Himalaya at 13.4%

6.     Amongst the 31-40 ranked Corporates, Bharat Serums grew at 32.2%, followed by Meyer Organics at 17.0% and JB Chemicals at 12.9%

7.     Amongst the 41-50 ranked Corporates, Boehringer Ingelheim had the highest growth at 44.7%, followed by Janssen at 28.5% & Win-Medicare at 22.6%

8.     Amongst the 51-60 ranked Corporates, Fresenius Kabi grew at 55.7%, followed by Centaur at 24.4% & Corona at 24.2%

9.     Amongst the 61-70 ranked Corporates, RPG grew at 31.7%, followed by Biological E at 19.1%  and Geno at 15.1%

10.  Amongst the 71-80 ranked Corporates, Danone grew by 57.5%, followed by Samarth at 32.9% & British Biologicals at 26.2%

11.  Amongst the 81 -90 ranked Corporates, Natco grew at 47.6%, followed by Roche at 21.0% and Med Manor at 17.1%

12.  Amongst the 91 -100 ranked Corporates, Gland Pharma grew at 76.7%, followed by Koye at 46.1% and Curatio at 15.0%

13.  Amongst the 101-150 Corporates, high growth ones were - Bennet, KLM Pharma, Kepler HC, Eisai, Reliance LS, UTH, Delcure, Comed, MSN, La Renon, Icon, Saffron amongst others

14.  Amongst the 151–200 high growth Corporates were Celon Labs, Brinton Pharma, Indian Immunologicals, Innovcare, Medo Pharma, Delvin, Arinna amongst others

15.  Sun Pharma crossed Rs. 9000 crore mark, Micro Rs. 2000 crore, Corona Rs. 300 crore, Jenburkt Rs. 100 crore and Unimarck crossed Rs. 50 crore mark on MAT basis


1.     Abbott HC grew at 12.8% whereas Abbott India grew at 17.1% during the previous month

2.     Zuventus grew at 29.0%, and Novo Nordisk at 28.0%

New companies (launched during last 36 Months):

1.     The new companies were Koye Pharma followed by Saffron Therapeutics and Brinton Healthcare

2.     Koye Pharma crossed Rs. 100 crore within 36 months amongst new companies

Sep -16 quarter highlights:

1.     Market grew at 12.6% during this quarter against 11.4% during the same quarter last year

2.     Corporates having high quarter performance include Boehringer, Centaur, Corona, Zuventus, Bharat Serums, Indoco, Aristo, Unichem, Medley, Eris, Hetero,  Win – Medicare, Micro*, Blue Cross, JB Chemicals, Ipca, Mankind, Janssen, Wallace*, Systopic, Emcure*, USV, Himalaya, Sun* amongst others in Top 60

Indian V/s MNC:

1.     Indian companies growth was 13.3% versus 10.0% for MNCs

2.     Amongst the MNCs, Boehringer grew at 44.7%, followed by Janssen at 28.5% and Abbott at 16.5%

3.     Under the Non-NLEM category Indian companies grew at 15.7% whereas MNCs grew at 12.6%

NLEM, Non NLEM & Non-Scheduled Para 19 market:

1.     The NLEM 2013 listed molecules segment grew at -1.0% whereas the non-NLEM grew by 15.0% resulting in an overall growth of 12.6%

2.     NLEM & Non-NLEM segments had unit growth of 7.6% and 5.4% respectively.


1.     10 therapies had faster growth than the overall growth

2.     Respiratory grew at 16.8%, Gastrointestinal at 10.9% , Pain & Analgesics at 13.7% whereas Anti-infectives grew at 6.7%

3.     Among chronic care, Anti-diabetic grew at 20.0%, Cardiac at 11.9%, and Neuro/CNS at 11.9%

4.     Anti-Malarials grew at 38.6%, VMS Market at 11.4%

5.     Derma market grew by 10.8% & Urology Market at 14.6%.

Regional Dynamics:

1.     14 regions out-grew the overall market growth

2.     Karnataka had the highest growth at 22.2%, followed by Saurashtra at 20.8% & Chattisgarh at 17.5%


1.     Amoxycillin + Clavulanic Acid  grew at 7.3% & Glimepiride + Metformin grew at 30.2%

2.     The Paracetamol grew at 33.6%, Atorvastatin at -6.9%, Probiotic Microbes at 14.6%, Bacillus Clausii at 22.1%, Cefixime at 5.6%, Pantoprazole at 9.7%, Montelukast + Levocetrizine at 31.6%, Glimepiride + Metformin + Pioglitazone at -19.7%, Vitamin-D at 5.0%, Hydroquinone + Mometasone + Tretinoin at 4.3%, Voglibose + Metformin + Glimepiride at 43.8%, Rosuvastatin at 21.6%, Protein Supplements at 31.8%, Azithromycin at 2.3%, Calcium Carbonate + Vit D3 at 7.0%, Paracetamol + Phenylephrine + Chlorpheniramine at 34.5%, Meropenem at 37.2%, Montelukast + Fexofenadine at 26.8%, Diclofenac at 18.7%, Telmisartan at -6.0%, Levetiracetam at 14.8%, Cefpodoxime at 29.9%, and Ranitidine at 16.6%.


1.     Mixtard was no. 1 with Rs. 43 crore sales, followed by Glycomet GP & Monocef at Rs. 34 crore, Spasmoproxyvon Plus at Rs. 31 crore, and Galvus Met at Rs. 29 crore

2.     Brands which gained ranks include Revital H (+44), Ecosprin AV (+36), Monocef O (+35), Udiliv (+32), Zoryl M (+31), Aciloc RD (+29), Gluconorm G (+28), Dolo (+27), Meronem, Duolin (+22), Novomix, Istamet (+20), Allegra, Ascoril Plus (+19),  Duphaston, Gemer (+18), Aciloc, Duphalac (+17), Trajenta (+15), Chymoral Forte (+13), Pan D, Dolonex (+12), Sinarest, Ultracet (+11), Jalra M, Eltroxin (+10), Levipil, Combiflam, Mucaine (+9), Pantocid (+8), Electral Powder (+7), Voveran, Glycomet, Deriphyllin (+6), Lantus, Galvus Met, Rosuvas, Levera (+5), Glycomet GP (+4) amongst top 100 Brands

3.     In 101-200 bracket, Similac, Corex DX, Candiforce, Glimestar M, Zyrop, Lonopin, Cypon, Cilacar, Neurobion Forte are few brands which gained ranks

4.     Few brands that moved up ranks fastest into Top 300 bracket were Panderm NM, Jardiance, Rotateq, Glioz, Docetere, Sebamed, Ryzodeg, Sumo L, Caripill amongst others

5.     300th ranked brand was Paraxin from Abbott

New Launches in IPM:

1.     Total 270 brands & 471 SKUs were launched during the previous month

2.     New molecule launched was Lurasidone

3.     Itraconazole saw 2 more players wheras Teneligliptin saw 5 new brands

4.     Top 5 new brands were Kabimethate, Luramax, Ambrodil Plus RF, Lurasid & Hilo

5.     Biggest launch by MNCs was Tasigna HGC by Novartis

6.     Within the VMS category new launches were Co-ostivestin, Cissact (Zydus), Welorich (Cipla)

7.     Rozalet (Sun), Fibricor (Zuventus), Telma D (Glenmark) were new brands in cardiac segment

8.     Within Anti-diabetic new launches were - Glypten (Franco), Vedator GM (Vidakem), Tenepan M (Panacea), Tenipack (Koye), Glitz, Glitz M (Ordain)

9.     Derma saw Afdern MN (Anglo French), Puradine OZ (Leeford) as new launches

10.  Goecyst Plus, Indulact (Koye), Cadrich (Zydus*), Coedhea (Koye) were new launches in Gynec

11.  In Pain & Analgesics Lubrione (Zuventus), Dolostat Plus R (Blue Cross), Intagesic SP (Intas) were new launches

12.  Respiratory  had Respizen (Zuventus), Trikast (Hetero) as new launches



Comment 32
Name *
Email ID *
Recent Blog Posts
arrow Thailand’s hospital sector commands much more value than India
arrow Over USD3B of PE commitment for May’19
arrow Destroying credibility of The Economic Times
arrow April’19 Score: China – 18, India – 0
arrow Is threat to offline retail in consumer electronics from e-commerce overhyped?
arrow Chinese pharma companies on in-licensing spree
arrow Healthcare sector drew USD24B+ of PE investment in 2018
arrow Indian Pharma Domestic Formulation - March Update
arrow Indian Pharma Domestic Formulation - February Update
arrow Indian Pharma Domestic Formulation - January Update
arrow Can Byju’s go the way of Educomp and other Digital Classroom companies?
arrow Indian Pharma Domestic Formulation - November Update
arrow Early stage and MSME funding witnesses subdued action in November 2018
arrow Indian Pharma Domestic Formulation September Update
arrow USD 2.7 B of private equity investment and 24 SME IPOs in Sep’18
arrow 2018 Award for India’s Most Pusillanimous Company Board
arrow FMCG valuations have peaked, says report by Jeffreys
arrow Long way to go for Indian construction companies
arrow Wholesale dependence high in FMCG space
arrow Fintech is hot globally, headed for a record year
arrow CCI penalises Glenmark & 2 more pharma companies in distribution case
arrow RBI Report on State Finances for FY17-18 shows slippages
arrow USD 1.85 B of VC/PE investment reported in Global Healthcare space in Jun’18
arrow USD 1.1 B of private equity investment reported in Jun’18 in India
arrow USD 2.3 B of private equity investment reported in May’18 in India
arrow USD 2.2 B of private equity investment reported in Apr’18 in India
arrow China emerging as the R&D leader in oncology biotech?
arrow USD 1.9 B of private equity investment reported in Mar’18 in India
arrow FDCs issue moving further, CDSCO committee calls stakeholders for data
arrow DTAB recommends prescription switch by pharmacies / chemists
arrow Indian Pharma Market Feb'18 Update - Steady Growth Continues
arrow USD 1 B of private equity investment reported in Feb’18 in India
arrow Indian Domestic Pharma January'18 Update - Upward Growth March Continues
arrow USD 2.3B of private equity investment reported in Jan’18 in India
arrow Global Healthcare PE Deals Tracker - January 2018 Update
arrow Apollo group well on its way to creating a pharma distribution behemoth
arrow USD 864m of private equity investment reported in Dec’17
arrow Global Healthcare PE Deals Tracker - December'17 Update
arrow Indian Pharma Market Dec'17 Update - Growth remains steady at 7.8%
arrow Indian Pharma Market Nov'17 Update - Growth inching up, touches 8.1%
arrow Strong brands equals supernormal profits, shows MDH
arrow Indian Pharma Market Oct'17 Update - Growth inching up, touches 6.5%
arrow USD 1.2B of deals in global healthcare space in Oct'17
arrow USD 1380m of private equity investment reported in Oct’17
arrow Spurious RTI data – 40% vacancy in Mum-Ahd trains
arrow RBI’ Revenge
arrow Tax Collections in India – A primer
arrow Ratan Tata is right – very few disruptive startups get funded
arrow USD 782m of private equity investment reported in Sep’17
arrow VC/PE investments hit a high in Aug 2017
arrow VC/PE investments cross USD1B in Jul’17
arrow VC/PE investment headed for a big year at half way mark
arrow Sharp reduction in the inventory days
arrow Indian Pharma Market May'17 Update - growth further slows down further, down to just over 7%
arrow A strong move by the new USFDA Head to shorten generic approvals timelines
arrow No more approval for new drugs by the state FDAs
arrow Another month of >USD1B reported investment
arrow Imminent ‘generics-isation’ of the Indian pharma – a blessing in disguise
arrow Indian Pharma Market2017 January Update - Slow Start to the New Financial Year
arrow Indian handicraft exports are booming
arrow Robust inflows continue in VC/PE deal space
arrow Will Electric Vehicles replace normal vehicles?
arrow What Young Think?
arrow Mobile subscriber base at 895 million, up by increased by 5.68 million in March
arrow Government to launch 3 year plans
arrow H1B – No legislative changes as yet!
arrow India retains its place as the fastest growing economy in the World
arrow Vacancies are rampant!
arrow Focus on improving Ease of Doing Business within India
arrow Controlling Population Growth
arrow Digital Payments is the Way
arrow Exports and Imports Increase in March
arrow Controlling Food Wastage
arrow 5G is Here!
arrow Economic data turns adverse
arrow Salaries in India
arrow RBI expects higher inflation
arrow Jio is shaking up the telecom industry
arrow Weather related industries sees Spike in Sales
arrow Manufacturing picking up as March data shows
arrow Water availability numbers in India make for shocking reading
arrow India needs to tap its tourism potential better
arrow Mar’17 sees smart revival in VC/PE deal space
arrow Software as a Service business has come a long way in India
arrow GST is becoming a reality – Advantages of GST
arrow Making India a manufacturing powerhouse
arrow People are worried around the globe
arrow Startup Fund will change Indian Entrepreneurship
arrow Farm Loan Waiver – A Bad Idea?
arrow Smart Cities – Not Taking Off as Yet
arrow Trends in Technology
arrow Nordic nations are the world's happiest
arrow Vodafone Idea Merger to create largest Telecom company in India
arrow Genomic Research – a new Sunrise Industry?
arrow Currency levels reach 70% of pre-demonetisation levels
arrow New National Health Policy unvieled
arrow Reforms in financial sector expected
arrow Rising inflation will prevent rate cuts by RBI
arrow Solar Power prices hit a new low
arrow UP Election Victory may drive Reforms
arrow Rich in India - the Hurun List
arrow Japanese funds are investing in Indian Startups
arrow India Inc and the new normal in CEO salary
arrow Giving in India
arrow Startup India - a good start
arrow Hubtown loses case, now what about Tata Docomo?
arrow Israel – the startup haven
arrow Crowdfunding is huge
arrow The problem of NPA
arrow Corporates are paying attention to CSR
arrow Note ban: Impact on Economy
arrow Time to reboot for Indian IT
arrow India is making rapid strides in Space busines
arrow E-Retailing losses – Any lessons?
arrow Indian Pharma Market2017 January Update - Double Digit Growth Continues
arrow Crisis in Infosys
arrow Henry Schein: A remarkable growth story
arrow Angel investing in public markets
arrow Jan’17 sees tepid VC/PE activity
arrow Why is Divi’s stock price falling?
arrow Dec'16 witnesses USD2.4B of VC/PE investment
arrow Indian Market December 2016 Update - Anti-Diabetic and Cardiac comes to the rescue of the overall ma
arrow Indian Pharma Market - Novemeber Update
arrow India emerges tops in JBIC FDI survey for 2016
arrow VC/PE deal space back to pedestrian pace in Nov’16
arrow Demonetisation to have several long term benefits for India
arrow Oct’16 sees improvement in VC/PE deal space
arrow Indian Pharma Market September 2016 Update - Double Digit Growth Continues
arrow August sees better deal traction in private space
arrow FMCG companies hope for revival in rural demand
arrow VC/PE investments crater in June
arrow Expanding distribution helps Marico beat GDP growth
arrow Indian Pharma Market May 2016 Update - Growth improves, but still in single digit
arrow Future Consumer – as confused as ever
arrow Valuation of a few ecomm companies
arrow VC/PE investments slip again in May
arrow QSR companies continue to struggle for growth
arrow Apr’16 witnesses rebound in VC/PE deal amounts
arrow DS Group’s candy Pulse makes electrifying launch
arrow Consolidated impact of three key policy decisions on the pharma market - 4.5% of the overall market
arrow Mar’16 witnesses ~USD 504m of VC/PE investments
arrow Impact of the banning of nearly 350 FDCs by the government last week
arrow Indian Pharma Market - February 2016 update: steady growth continues
arrow Agree with Murthy, ‘delivery food tech’ is not a business
arrow Jan’16 starts with USD 800m of VC/PE investments
arrow Indian Pharma Market - January 2016 update: steady growth continues
arrow Indian Pharma Market December 2015 Update - steady double digit growth continues
arrow Indian Pharma Market - November Update
arrow Indian Pharma Market - October Update: a blockbuster month
arrow VC/PE investments for 2015 close at USD 14B
arrow USD 1.27B of VC/PE transactions in November’15
arrow Winner takes all in tech and e-commerce
arrow VC/PE investments USD 12B for Jan-Oct-15
arrow The thuggery of AIOCD needs to be stopped
arrow Indian Pharma Market - September Update: relatively slower month
arrow Quality of accounting at Pharma companies going down
arrow Monthly VC/PE deal count touches all time high in Sep’15
arrow India has the most US FDA approved API plants in the world
arrow Vaccine companies are raking it in
arrow India most profitable pharma company is…Serum Institute
arrow The great Indian infra asset sale
arrow Indian pharma needs a period of valuation consolidation
arrow Indian Pharma Market August 2015 Update - double digit growth continues
arrow Is Sun Pharma losing the plot?
arrow USD 1.3b of private equity investments in Aug’15
arrow Government VC fund to support pharma R&D
arrow Cipla’s consumer health business to roll from FY17
arrow PE exits at all-time high in 2015
arrow MSO numbers expected to surge with DAS Phase-III coming up
arrow Annual Capacity Addition Targets for Solar Power set
arrow India best performing emerging market so far
arrow Indian Pharma Market July 2015 Update - double digit growth continues
arrow July’15 sees 91 VC/PE deals aggregating ~USD 1.7b
arrow Modern Dental Lab files for IPO
arrow Syngene business better than Biocon?
arrow Regulation does not pose a hurdle for online pharma
arrow Indian Pharma Market June 2015 Update
arrow More banks launching m-wallets
arrow June’15 sees 65 VC/PE deals
arrow Innovation and The lowest BRIC
arrow Indian Pharma Market April 2015 Update
arrow VC/PE sector headed for a big year
arrow LED market to grow at 40% plus
arrow Zydus planning a big acquisition?
arrow Indian Pharma Market March 2015 Update
arrow Zydus group announces big investment in hospitals
arrow Mar’15 sees 57 VC/PE deals aggregating USD735m
arrow Banks commit to funding 60,000MW of renewable energy
arrow Can change in packaging raise sales by 50%?
arrow Adlabs IPO focusses attention on Indian Amusement park business
arrow Indian Pharma Market February 2015 Update
arrow ITC targets Rs 1 trillion turnover from FMCG
arrow 53 VC/PE transactions recorded in Feb’15
arrow India’s chocolate market crosses Rs 100B mark
arrow Indian snack food market growing at 25% CAGR
arrow Haldiram’s combined revenues is Rs 3500 crore!
arrow Auto sales growth muted in January
arrow Jan’15 sees $1.4 billion of venture capital investment
arrow Autopart retail a very profitable business in the US
arrow Indian Pharma – Likely Future Trends
arrow Indian Pharma Market December 2014 Update
arrow Car Care an attractive business
arrow Oil price headed to $20 a barrel?
arrow 3M’s car detailing business now Rs 175 crore annually
arrow BRIC to IC
arrow Deal count up sharply in 2014
arrow India patent data proves critics wrong
arrow Impact of Rouble depreciation on the Indian pharma industry
arrow Spice 20% market share up for graps
arrow Indian Pharma Market November 2014 Update
arrow Shocking practices of Indian pharma
arrow InMobi not quite the investor darling now?
arrow Will India pharma look more closely at US nutra market?
arrow Jubilant Foodworks continues to face adverse demand environment
arrow Brokers hot on agrochem sector
arrow Samsung now India’s second largest consumer company
arrow Flipkart posted Rs 28bn revenue in FY14
arrow Apple revenues up 10x in 4 years in India
arrow Honda Motorcycle catching up with Bajaj Auto in motorcycle market
arrow 100 mid market hotels on sale
arrow Hardcastle plans to more than double outlets in 3-5 years
arrow Flipkart Big Billion Day: Beginning of the end for Flipkart?
arrow NPPA Loses Pricing Power
arrow Another online doctor appointment site gets funded
arrow Online ad market in India to reach Rs 3,575 cr by FY15
arrow Sutlej planning big expansion in home textiles
arrow Biyani claims food park is necessary for food business
arrow The outdated moped still clocks big numbers!
arrow Brick and mortar furniture chains scaling back
arrow Startups creating new categories in processed foods
arrow Pro Kabaddi was a big hit
arrow Market excited by Cipla’s combination inhaler launch
arrow Dental care chain MyDentist raising funds again
arrow Wholesalers take to sourcing from e-commerce sites
arrow Massive housing supply glut in Mumbai
arrow Britannia aims to take leadership from Parle in biscuits
arrow Indian Pharma Market July 2014 Update
arrow Arvind Mills aims to double turnover in 4 years
arrow Logistics Stocks give super returns
arrow Dai Ichi rises 15% today, hits new all time high!
arrow Bullish on Chemical Sector
arrow Godrej Appliances expects to grow 30%
arrow 10th July order of NPPA on price control
arrow DRL is sharply hiking R&D spends
arrow Why did Congress lose so badly? Simple answer – the voter knows
arrow Connexios Deal with Boeringher Ingelheim
arrow Yum! Brands to triple store count
arrow CPVC: A rapidly growing market
arrow Kotak PE set for bumper returns in Indus Biotech
arrow Mobile data usage surging
arrow India’s toothpaste market witnessing strong competitive activity
arrow Dabur still reporting volume growth in teens
arrow Operational costs galloping for Domino’s?
arrow Indian Pharma Market - January 2014 Update
arrow India's per capita footwear consumption is ~2 pairs
arrow TVS is outperforming for a change
arrow Titan reaches 100+ towns now
arrow Slowdown at V-Guard
arrow Indian Pharma Market - December 2013 Update
arrow Cadila set for sharp growth in US markets
arrow We remain bearish on economic scenario
arrow Car sales end negative for 2013
arrow Rural consumer taking to packaged fruit juice
arrow Adhesives market in India
arrow Retailers report worst festive sales in 10 years - Mint
arrow Festive season missing the retail spark this time
arrow 2 wheeler market to grow in single digits henceforth?
arrow Innerwear market continues it hot streak
arrow Has Crisil got its QSR numbers wrong?
arrow Goldman remains hyper bullish on Jubilant Food
arrow Why we think organised tyre retail is a good business
arrow Impact of ceiling price on drugs (270 drugs)
arrow Indian Pharma Market - July Update
arrow MyTVS is the leader in multibrand car servicing
arrow Growth grounds to a halt for Jubilant Foods
arrow Dental demand in India varies strongly with per capita income
arrow Finolex Cables wants to do a Havells
arrow HUL has 3 new Rs 10bn brands
arrow A monkey would have made money in stocks in 2012
arrow Angel Broking puts a Buy on TTK Healthcare
arrow Fabric wash market currently at $2.8bn, a mature market
arrow Distribution emerging as a key factor in FMCG, says report
arrow Life gets tougher for food chains as consumers reduce spends
arrow Growth March of Indian Pharma Market Continues
arrow Deepening consumer gloom
arrow Ikea’s nod a great positive for India
arrow Currently there is potential for 2453 Domino’s outlets, says Goldman Sachs
arrow Institutional brokers highly bullish on Jubilant Foodworks (JFL)
arrow Lavazza looking to exit Barista, says The Economic Times
arrow Café Coffee Day still to get profitability right
arrow Jubilant Foodworks Q2 results, 42% yoy revenue growth
arrow McDonald’s needs to get its act together in India
arrow Government plans a crackdown on pharma firms selling drugs as dietary supplements